Pacira | PCRX - Assets


Pacira reported $1.26B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Assertio Holdings USD 319.77M 46M Sep/2025
Astellas Pharma JPY 3.6T 153.62B Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cara Therapeutics USD 43.75M 4.8M Jun/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Novo Nordisk DKK 542.9B 30.61B Dec/2025
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.26B 32.66M Dec/2025
Perrigo USD 8.54B 1.55B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Supernus Pharmaceuticals USD 1.45B 32.89M Dec/2025
Teva Pharmaceutical Industries USD 40.75B 892M Dec/2025
Xeris Pharmaceuticals USD 370.19M 35.5M Sep/2025
Xoma USD 263.15M 39.7M Sep/2025
Zoetis USD 15.47B 308M Dec/2025